Naltrexone and Disulfiram in Patients With Alcohol Dependence and Current Depression
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Although disulfiram and naltrexone have been approved by the Food and Drug Administration for the treatment of alcoholism, no medications have been approved for individuals with alcohol dependence and comorbid psychiatric disorders. In particular, the effect of these medications on alcohol use outcomes and on specific psychiatric symptoms is still unknown in patients with the most common co-occurring disorder, major depression. METHOD: Two hundred fifty-four patients with a major Axis I psychiatric disorder and comorbid alcohol dependence were treated for 12 weeks in an outpatient medication study conducted at 3 Veterans Administration outpatient clinics. Randomization included (1) open randomization to disulfiram or no disulfiram, and (2) double-blind randomization to naltrexone or placebo. This resulted in 4 groups: (1) naltrexone alone, (2) placebo alone, (3) disulfiram and naltrexone, and (4) disulfiram and placebo. Primary outcomes were measures of alcohol use. Secondary outcomes included psychiatric symptoms assessed by the Hamilton Depression Rating Scale, alcohol craving, gamma-glutamyltransferase levels, and adverse events. RESULTS: One hundred thirty-nine subjects (54.7%) met the current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for major depression. There was no relationship between the diagnosis of depression and medication treatment on alcohol use outcomes, psychiatric symptoms, or the reporting of side effects for these medications. There was a significant interaction between diagnosis, medication group, and craving, where subjects with depression on disulfram reported lower craving over time than subjects with depression on naltrexone. CONCLUSIONS: The results suggest that disulfiram and naltrexone are safe pharmacotherapeutic agents for dually diagnosed individuals with depression for the treatment of alcohol use disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Agents for primary alcohol use disorder may also show benefits in BD, such as disulfiram (level 3),688, 689, 690, 691 naltrexone (level 3)692, 693, 694, 695 and gabapentin (level 4).696, 697”
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory
Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974) · Behavioral Science · doi:10.1002/bs.3830190102 · Cited by 4,604
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962 · cited 7×
“This resulted in the following groups: (1) naltrexone alone, (2) placebo alone, (3) disulfiram and naltrexone, and (4) disulfiram and placebo.”
BackgroundMethodInfluentialThe Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757
Treatment of Depression in Patients With Alcohol or Other Drug Dependence: A Meta-analysis
Nunes, E. V., & Levin, F. R. (2004) · JAMA · doi:10.1001/jama.291.15.1887 · Cited by 532
Anton, R. F. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830030047008 · Cited by 511
Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram
Carroll, K. M., Nich, C., Ball, S. A., Mccance, E., & Rounsavile, B. J. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9357137.x · Cited by 375
Self-citationCroop, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830240090013 · Cited by 211 · cited 2×
“This resulted in the following groups: (1) naltrexone alone, (2) placebo alone, (3) disulfiram and naltrexone, and (4) disulfiram and placebo.”
BackgroundMethodNaltrexone for alcohol dependence: a randomized controlled trial
Morris, P. L. P., Hopwood, M., Whelan, G., Gardiner, J., & Drummond, E. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.961115654.x · Cited by 200
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Alcohol use disorder and depressive disorders
McHugh, R. (2019) · Alcohol Research: Current Reviews · doi:10.35946/arcr.v40.1.01 · Cited by 517
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis
McPheeters, M., O’Connor, E. A., Riley, S., Kennedy, S. M., Voisin, C., Kuznacic, K., Coffey, C. P., Edlund, M. D., Bobashev, G., & Jonas, D. E. (2023) · JAMA · doi:10.1001/jama.2023.19761 · Cited by 285
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Treatment of substance abusing patients with comorbid psychiatric disorders
Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.09.010 · Cited by 284
Ramasubbu, R., Taylor, V. H., Samaan, Z., Sockalingham, S., Li, M., Patten, S., Rodin, G., Schaffer, A., Beaulieu, S., & McIntyre, R. S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400110 · Cited by 206
Foulds, J., Adamson, S. J., Boden, J. M., Williman, J. A., & Mulder, R. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.024 · Cited by 155
Laaksonen, E., Koski-Jännes, A., Salaspuro, M., Ahtinen, H., & Alho, H. (2008) · Alcohol and Alcoholism · doi:10.1093/alcalc/agm136 · Cited by 147
Menopause, ageing, and alcohol use disorders in women
Milić, J., Glišić, M., Voortman, T., Pletsch‐Borba, L., Asllanaj, E., Rojas, L. Z., Troup, J., Jong, J. C. K., van Beeck, E., Muka, T., et al. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.03.006 · Cited by 133
Medical Treatment of Alcohol Dependence: A Systematic Review
Miller, P. M., Book, S. W., & Stewart, S. H. (2011) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.42.3.b · Cited by 107
“Seven RCTs focusing on selective serotonin reuptake inhibitors (SSRIs) met our criteria and all were rated as having “Less Potential for Bias.””
InfluentialDrug-drug interactions in the treatment for alcohol use disorders: A comprehensive review
Guérzoni, S., Pellesi, L., Pini, L. A., & Caputo, F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.024 · Cited by 68
“In the case of a simultaneous administration with disulfiram or baclofen, no interactions are expected [141,142].”
BackgroundSinclair, J., Chambers, S. E., Shiles, C. J., & Baldwin, D. S. (2016) · Drug Safety · doi:10.1007/s40264-016-0416-y · Cited by 67
“The main evidence for using disulfiram in patients with alcohol dependence and comorbid Axis 1 disorders comes from the VA study reported by Petrakis and colleagues [59, 74, 76, 78] described above: none identified any specific concerns regarding the use of disulfiram in patients with psychotic spectrum disorders, PTS…”
Smith, J. P., Field, D. G., Bingaman, S. I., Evans, R., & Mauger, D. T. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182702f2b · Cited by 62
Endogenous opiates and behavior: 2007
Bodnar, R. J. (2008) · Peptides · doi:10.1016/j.peptides.2008.09.007 · Cited by 72
“associated with any incidence of current depression [973], and was effective in patients with personality disorders, alcohol dependence and comorbid Axis I disorders [999].”
BackgroundDiehl, A., Ulmer, L., Mutschler, J., Herre, H., Krumm, B., Croissant, B., Mann, K., & Kiefer, F. (2010) · Alcohol and Alcoholism · doi:10.1093/alcalc/agq017 · Cited by 49
Stokes, P. R. A., Jokinen, T., Amawi, S. O., Qureshi, M. M., Husain, M. I., Yatham, L. N., Strang, J., & Young, A. H. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720915420 · Cited by 53
“found a significant reduction in alcohol consumption and more consecutive days of abstinence associated with naltrexone or disulfiram treatment.(40) Effects of treatment on alcohol abstinence.”
BackgroundBeaulieu, S., Saury, S., Sareen, J., Tremblay, J., Schütz, C. G., McIntyre, R. S., & Schaffer, A. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400105 · Cited by 38
“No recommendations were possible for opiate SUD comorbid with BD. Finally, psychotherapies certainly are considered an essential component of the overall treatment of SUDs comorbid with mood disorders.”
InfluentialThe association between naltrexone treatment and symptoms of depression in opioid-dependent patients
Mysels, D. J., Cheng, W. Y., Nunes, E. V., & Sullivan, M. A. (2011) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2010.540281 · Cited by 38
“” On the other hand, a double-blind randomized controlled trial comparing naltrexone to disulfiram and placebo for the treatment of alcohol dependence found that naltrexone was associated with improved depressive symptoms over 12 weeks in patients with baseline current depression (12).”
BackgroundAlcohol Withdrawal and the Associated Mood Disorders—A Review
Ngui, H. H. L., Kow, A. S. F., Lai, S., Tham, C. L., Ho, Y., & Lee, M. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314912 · Cited by 39
Foulds, J., Sellman, J. D., Adamson, S. J., Boden, J. M., Mulder, R., & Joyce, P. R. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.11.052 · Cited by 39
“Lastly the potential influence of naltrexone on both drinking and depression outcomes in this study was not known, although it is now suggested naltrexone has little effect on depressive symptoms (Petrakis et al., 2007).”
BackgroundGinseng Extract G115 Attenuates Ethanol-Induced Depression in Mice by Increasing Brain BDNF Levels
Boonlert, W., Benya-aphikul, H., Welbat, J. U., & Rodsiri, R. (2017) · Nutrients · doi:10.3390/nu9090931 · Cited by 34
Pharmacological management of alcohol dependence: From mono-therapy to pharmacogenetics and beyond
Caputo, F., Vignoli, T., Grignaschi, A., Cibin, M., Addolorato, G., & Bernardi, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.004 · Cited by 36
Caputo, F., Francini, S., Brambilla, R., Vigna‐Taglianti, F., Stoppo, M., Re, A. D., Leggio, L., Addolorato, G., Zoli, G., & Bernardi, M. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.12.005 · Cited by 34
Li, J., Wang, H., Li, M., Shen, Q., Li, X., Rong, X., & Peng, Y. (2020) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13437 · Cited by 30
Nunes, E. V., & LEVIN, F. R. (2008) · Psychiatric Annals · doi:10.3928/00485713-20081101-05 · Cited by 29
Pharmacotherapy of Alcohol Use Disorders and Concurrent Psychiatric Disorders: A Review
Lev-Ran, S., Balchand, K., Lefebvre, L., Araki, K. F., & Le Foll, B. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700603 · Cited by 26
The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease
Matters, G. L., Harms, J. F., McGovern, C. O., Fitzpatrick, L. R., Parikh, A., Nilo, N., & Smith, J. P. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910802131469 · Cited by 27
“While naltrexone has been approved by the Food and Drug Administration for alcohol withdrawal syndromes (Petrakis et al., 2007) at a dose of 50 mg daily, it is unknown how this higher dose affects inflammatory responses and cytokines.”
BackgroundPharmacotherapeutic options for co-morbid depression and alcohol dependence
Hillemacher, T., & Frieling, H. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561870 · Cited by 25
“used effectively and safely in individuals with current depression and alcohol dependence [43].”
BackgroundInfluentialMutschler, J., Dirican, G., Funke, S., Obermann, C., Grosshans, M., Mann, K. F., Kiefer, F., & Diehl, A. (2011) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3182216fd5 · Cited by 17
Status of disulfiram in present day alcoholic deaddiction therapy
Saldanha, E., & Palatty, P. L. (2011) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.75557 · Cited by 18
“[22] Other studies supporting for long term DSM management and it being better than other treatment protocols are Petrakis et al , [23] and De Souza.”
Disulfiram in the management of alcohol dependence: A comprehensive clinical review
Kalra, G., Sousa, A. D., & Shrivastava, A. (2014) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2014.41007 · Cited by 40
Miller, C. N., Ruggery, C., & Kamens, H. M. (2018) · Alcohol · doi:10.1016/j.alcohol.2018.11.006 · Cited by 14
Therapeutic options and challenges for substances of abuse
Gardner, T. J., & Kosten, T. R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/tgardner · Cited by 14
Course of Late-Life Depression With Alcoholism Following Combination Therapy
Gopalakrishnan, R., Ross, J., O’Brien, C. P., & Oslin, D. W. (2009) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2009.70.237 · Cited by 12
“Likewise, anti-alcohol agents such as naltrexone (Revia) or disulfi ram (Antabuse) have little impact on depression outcomes (Petrakis et al., 2007).”
BackgroundYoon, G., & Petrakis, I. L. (2018) · Current Addiction Reports · doi:10.1007/s40429-018-0213-z · Cited by 12
Self-citationCo-occurring Mood and Substance Use Disorders
Wai, J. M., Shulman, M., Nunes, E. V., Hasin, D. S., & Weiss, R. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-36391-8_91 · Cited by 13
Cambio de paradigma en el tratamiento del alcoholismo de baja gravedad
Serecigni, J. G. (2011) · Adicciones · doi:10.20882/adicciones.126 · Cited by 14
Pharmacotherapy of Alcohol Dependence: Improving Translation from the Bench to the Clinic
Little, H. J., McKinzie, D. L., Setnik, B., Shram, M. J., & Sellers, E. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00025-4 · Cited by 9
Comorbidity of Alcohol Use Disorder and Depression: A Case Report and Review of the Literature
Tseng, I., Ganz, A., Mitton, A. G., & TSUANG, J. W. (2017) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0000000000000106 · Cited by 9
Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series
Caputo, F., Maremmani, A. G. I., Addolorato, G., Domenicali, M., Zoli, G., d’Amore, A., Maremmani, I., & Bernardi, M. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116629126 · Cited by 8
“The results obtained with disulfiram plus NTX did not differ from those obtained with mono-therapy in alcoholics with psychiatric co-morbidities (Petrakis et al., 2005; Petrakis et al., 2006a, 2006b, 2007).”
ResultSpiegel, D. R., Mccroskey, A. L., Puaa, K., Meeker, G., Hartman, L., Hudson, J., & Hung, Y. C. (2016) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000166 · Cited by 8
“Aside from early clinical reports, there are few studies of the use of disulfiram in patients with comorbid psychiatric disorders.(3) Regardless, there have been case reports, both inmonotherapy and combination therapy, showing the development of both psychoses and mania (see Table 1 for a review).”
BackgroundMandaji, J. V. G., Pedro, M. O. P., Leopoldo, K., Alemar, J. P., Torales, J. C., Ventriglio, A., & Castaldelli-Maia, J. M. (2025) · Brain Sciences · doi:10.3390/brainsci15060542 · Cited by 5
Samokhvalov, A. V. (2021) · The Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000125 · Cited by 4
“Alcohol consumption was predictably improved with the use of naltrexone or disulfiram.(36)”
Mangot, A. G., Murthy, V., & Jamale, S. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.05.002 · Cited by 4
Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need
de Jonge, D., van der Meer, P. B., Kramers, C., & Schellekens, A. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01567-4 · Cited by 3
Depression und Alkoholabhängigkeit: Eine therapeutische Herausforderung
Wilhelm, J., Heberlein, A., & Hillemacher, T. (2012) · Nervenheilkunde · doi:10.1055/s-0038-1628165 · Cited by 2
Vivitrol and Depression: A Case Report and Review of the Literature
Haglund, M., Mooney, L. J., Gitlin, M. J., FONG, T. W., & TSUANG, J. W. (2014) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0000000000000051 · Cited by 2
“likely due to its efficacy at increasing abstinence.(31,38,39) With regards specifically to long-acting depot naltrexone, a 2006 placebo-controlled randomized clinical trial of 2 different doses of IM naltrexone (192 vs.”
BackgroundNaltrexone and Disulfiram in Patients With Alcohol Dependence and Current Depression
Ballenger, J. C. (2008) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70834-x · Cited by 2
Almutairi, M. T., Alomair, R. M., Alharbi, A. A. H., Alshammari, M. S., Alharbi, S. S. A., Alotaibai, A. M., Alruki, K. O. A., Alruwaili, M. M., Alharbi, S. H. S., Aldalbahi, T. G. T., et al. (2020) · Journal of Angiotherapy · doi:10.25163/angiotherapy.4110067 · Cited by 1
Co-Occurring Mood and Substance Use Disorders
Nunes, E. V., Hasin, D. S., & Weiss, R. D. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_89 · Cited by 1
Reply to Comments by Mr Martin and Dr Beresford
Suh, J. J., Gallis, T. L., Kampman, K. M., & Pettinati, H. M. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000280313.96613.72 · Cited by 1
Johnson, B. A., & Ait‐Daoud, N. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_47 · Cited by 1
Dual Diagnosis and Post-Traumatic Stress Disorder
Blatt, L. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780190204747.003.0034
The new pharmacotherapies for alcohol dependence
Mason, B. J., & Jacobs, M. B. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511782107.021
Specialist treatment of drinking problems
Humphreys, K. N., & Lingford-Hughes, A. R. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316258057.014
Nava, F. A., Manzato, G., Rosa, S., & Caputo, F. (2017) · MISSION · doi:10.3280/mis45-2016oa4613
The Relationship of Alcohol Dependence to Monoamine Oxidase A
Matthews, B. A. (2015) · TSpace (University of Toronto)
Disulfiram and Its Use in Special Populations
Sousa, A. D. (2019) · Springer eBooks · doi:10.1007/978-981-32-9876-7_6
Gysling, E. (2008) · pharma-kritik · doi:10.37667/pk.2007.193
Treatment: Context and content
Humphreys, K. N., & Lingford-Hughes, A. R. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316258057.009
Subbaraman, M. S. (2012) · eScholarship (California Digital Library)
Current awareness in human psychopharmacology
(2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.886
(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00010-8
Alcohol use and depression - literature review
Płaczek, A., Białas, F., Baciur, P., Skowrońska, K., & Chmura, A. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.08.082 · Cited by 1
“[28] In contrast, the use of acamprosate in the treatment of alcohol use disorders showed similar effects with and without depression.”
BackgroundMethodBehandlung von riskantem, schädlichem und abhängigem Alkoholgebrauch
Kiefer, F., Hoffmann, S., Arens, J., Beutel, M., Bilke-Hentsch, O., Bischof, G., Bonnet, U., Bumb, J. M., Demmel, R., Diestelkamp, S., et al. (2022) · Springer eBooks · doi:10.1007/978-3-662-63677-0_3
Liang, Y., Roberts, J., Conigrave, K. M., Kim, S., & Doyle, M. (2023) · Drug and Alcohol Review · doi:10.1111/dar.13741
Réévaluation de l'apport du nalméfène au traitement de l'alcoolodépendance
Palpacuer, C. (2018) · theses.fr (ABES) · doi:10.70675/aa77e495z482ez45b0z9aabz3b0862e3413e
Sharif, A. F., Jahan, A. B., Salloum, I. M., & Francis, A. (2026) · American Journal on Addictions · doi:10.1111/ajad.70205
Metadata
- Authors
- Petrakis, I., Ralevski, E., Nich, C., Levinson, C., Carroll, K., Poling, J., & Rounsaville, B.
- Affiliations
- Yale University (US)
- Corresponding author
- Petrakis, Ismene
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-04
- Volume
- 27
- Issue
- 2
- Pages
- 160-165
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2066906665
- Cited by
- 66
- References
- 26
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 6 · 2015: 2 · 2014: 4 · 2013: 1 · 2012: 7
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- naltrexone, disulfiram, alcoholism, major depressive disorder, psychiatric comorbidity, alcohol craving, alcohol use outcomes, veterans, pharmacotherapy, gamma-glutamyl transferase, adverse events
- MeSH terms
- Alcohol Deterrents, Alcoholism, Bipolar Disorder, Connecticut, Major Depressive Disorder, Disulfiram, Double-Blind Method, Drug Therapy, Combination, Female, gamma-Glutamyltransferase, Gastrointestinal Diseases, Humans, Male, Massachusetts, Middle Aged, Naltrexone, Narcotic Antagonists, Psychiatric Status Rating Scales, Psychotic Disorders, Schizophrenia, Stress Disorders, Post-Traumatic, Veterans, Comorbidity, Treatment Outcome, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.